GlassScriptPhysician profile
Lily M Yang
NPI 1306208319
$5,870.37
in general payments reported to CMS, 2019-2025
35 companies · $787 in 2025
The $787 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $1,135 · 2021: $888 · 2022: $886 · 2023: $691 · 2024: $1,313 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,791.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $968.72 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $888.24 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $601.73 | 2020-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $458.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $452.12 | 2021-2024 | |
| Pfizer INC. | $355.18 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $278.21 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Radius Health, INC. | $266.06 | 2020-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $250.58 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $149.53 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $138.13 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $116.98 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.49 | 2020-2024 | Xifaxan |
| Shield Therapeutics INC | $79.05 | 2022-2024 | Accrufer |
| Biohaven Pharmaceuticals, INC. | $73.06 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $71.93 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $62.81 | 2022 | |
| Merck Sharp & Dohme LLC | $56.65 | 2019-2022 | |
| Gilead Sciences, INC. | $53.40 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.38 | 2019-2021 | |
| Edwards Lifesciences Corporation | $47.30 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Biohaven Pharmaceutical Holding Company LTD. | $45.45 | 2022 | |
| Vivus LLC | $42.30 | 2019-2021 | |
| Sanofi Pasteur INC. | $29.92 | 2022 | |
| Idorsia Pharmaceuticals US INC | $28.68 | 2022-2023 | Quviviq |
| Medicure Pharma INC. | $25.40 | 2021 | |
| Redhill Biopharma INC. | $23.28 | 2021 | |
| Teleflex LLC | $21.39 | 2023 | Urolift |
| Abbott Laboratories | $20.66 | 2023 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $20.00 | 2025 | Alvesco |
| Tempus Ai, INC | $19.51 | 2024 | Tempus Pixel |
| Esperion Therapeutics, INC. | $17.52 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $15.43 | 2021 | |
| Allergan, INC. | $14.24 | 2019 | |
| Eisai INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.